Trimuvira Corporate Presentation – 2nd Quarter 2023

June 1, 2023


We leverage a T cell’s recognition, activation, and signaling properties.

Triumvira’s proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.

For more information, please view our Corporate Presentation linked below.

Triumvira Corporate Presentation – 2mb PDF